VIVictoria Ivanov

Victoria Ivanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victoria Ivanov has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of inflammation and anti-inflammatory therapy in non-obstructive coronary artery disease (NOCAD)

    by Victoria Tofan, Mihail Popovici, Svetlana Cojocari, Victoria Ivanov, Mihaela Munteanu, Olga Dicusar, Diana Turlacova

    A large proportion of patients undergoing coronary angiography for angina pectoris do not have obstructive epicardial coronary arteries (ANOCA). In these patients, the prevalence of demonstrable ischemia (INOCA) varies between 10% and 30%, depending on the stress test performed. In recent years, research has focused on defining, classifying, and treating these patients according to INOCA endotypes. Inflammation and endothelial dysfunction play a key role in the onset and progression of chronic non-obstructive coronary artery disease (non-obstructive CAD), and identifying the correlation between these mechanisms and the disease itself may offer a targeted therapeutic strategy. This synthesis presents data from the last 10 years of the specialized literature, searched on Google Scholar and PubMed using keywords such as: inflammation in non-obstructive CAD, anti-inflammatory therapy in non-obstructive CAD. The selected studies, with scientific relevance, focused on the clinical importance, mechanism, evaluation, and management of non-obstructive CAD, with particular emphasis on the role of inflammation, endothelial dysfunction, and anti-inflammatory therapy

  • Open Access

    Current Evidence and Updates on the ANOCA/INOCA Concept

    by Mihaela Munteanu, Elena Anton, Lucia Ciobanu, Ion Popovici, Victoria Ivanov, Mihail Popovici

    Angina and ischaemia with non-obstructive coronary arteries (ANOCA/INOCA) are manifestations of chronic nonobstructive coronary artery disease (CAD) and refer to anginal symptoms or evidence of myocardial ischaemia without flow‐limiting obstructive lesions in the epicardial coronary arteries. Both entities share common vascular dysfunction mechanisms, called endotypes: endothelial dysfunction, impaired vasodilation, epicardial vasospasm, microvascular vasospasm and their combinations, and carry clinical aggravated significance by refractory angina, increased risk of major adverse cardiovascular events (MACE) and important impairment of quality of life (QoL). The updated (2024) European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndromes (CCS) pay increase attention to the subject of ANOCA/INOCA, providing diagnostic and therapeutic management recommendations. In order to achieve a personalized approach based on endotype and reliable evidence, the imperative for additional clinical research emerged, which would provide new effective diagnostic strategies and treatments for patients with ANOCA/INOCA syndrome.

  • Open Access

    Clinico-functional particularities of deceased patients with STEMI and NSTEMI 12 months after revascularization

    by Mihaela Munteanu, Svetlana Cojocari, Ion Popovici, Victoria Ivanov, Ion Moraru, I.I. Popovici, Lucia Ciobanu, Mihail Popovici

    Introduction: Acute myocardial infarction remains a leading cause of cardiovascular mortality worldwide [1 ]. However, ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI) patients differ in clinical profile - STEMIs often cause greater acute myocardial damage, whereas NSTEMIs tend to occur in older patients with more comorbidities [1]. These differences may impact 12-month outcomes. Aim: To compare the clinical and functional characteristics of patients who died within 12 months after revascularized STEMI versus NSTEMI, identifying factors associated with 1-year mortality. Methods: We performed a retrospective observational study of 1,078 revascularized MI patients (528 STEMI, 550 NSTEMI) followed for one year. We identified 176 patients who died within 12 months (95 STEMI and 81 NSTEMI) and analyzed their baseline risk factors, clinical presentation (including Killip class), laboratory findings, echocardiographic parameters (left ventricular ejection fraction - LVEF), and comorbidities. Results: The two groups of deceased patients were similar in age (~70 years). Both had very high prevalence of hypertension (>90%) and a low proportion of active smokers (~12%). NSTEMI decedents more often had diabetes (~55% vs 44%) and hypercholesterolemia (~79% vs 57%) than STEMI decedents. NSTEMI decedents also had more frequently a history of prior MI (~50% vs ~36%), stroke (23% vs 12%), or peripheral arterial disease (16% vs 8%). By contrast, cardiogenic shock at presentation was more common in STEMI decedents (Killip class IV in 27% vs 16%). Severe left ventricular dysfunction (LVEF less than 30%) was present in about half of the patients in both groups. Acute atrial fibrillation occurred more often in STEMI (30% vs 18%). Conclusions: Within 12 months post-infarction, patients dying after STEMI had more severe acute presentations (more cardiogenic shock and arrhythmias), whereas those dying after NSTEMI had a higher burden of risk factors and comorbidities. Nonetheless, both cohorts exhibited significant left ventricular dysfunction and high complication rates, indicating that both the acute infarct severity and underlying chronic conditions contribute to 1-year mortality after MI.

  • Open Access

    Rate, clinical and management characteristics of patients with chronic non-obstructive coronary artery disease (NOCAD)

    by Olga Dicusar, Victoria Tofan, Diana Turlacova, Mihaela Munteanu, Mihail Popovici, Victoria Ivanov, Ion Popovici, Lucia Ciobanu

    Purpose: To assess the rate of non-obstructive CAD among patients with stable coronary artery disease and to evaluate the clinical, diagnostic and treatment features of this population. Material and Methods: The operative protocols and medical records of 3,200 patients who underwent coronary angiography in two cardiac catheterization centers in Moldova between January 1 and August 1, 2024, were analyzed to determine the rate of non-obstructive CAD. Clinical, demographic, diagnostic, and treatment data were collected from 200 consecutive patients with non-obstructive CAD. Results: The calculated rate of non-obstructive CAD was 43.4%, with a female predominance of 61%. The mean age of patients was 64.7±8.8 years. The most common risk factors were hypertension (87%) and dyslipidemia (73%), while diabetes mellitus was diagnosed in 26%. Only 47% of patients reported typical angina pain, and just 23% had objective evidence of ischemic changes on non-invasive testing. Microvascular angina was diagnosed in 69% of cases, and vasospastic angina in 6%. Antianginal treatment included beta-blockers (69%), calcium channel blockers (52%), nitrates (4%), and trimetazidine (8%). Baseline therapy included ACE inhibitors (77%), statins (72%) and antiplatelets (49%). Conclusions: The rate of non-obstructive CAD evaluated in two PCI centers in Moldova was 43.4%, with a predominance of women accounting for 61%. The diagnosis of non-obstructive CAD presents a challenge for clinicians due to the atypical clinical presentation (typical anginal pain in only 47% of cases), non-informative non-invasive tests (objective evidence of ischemic changes detected non-invasively in 23% of cases), and the unavailability of invasive coronary testing.

  • Open Access

    Management of patients with acute myocardial infarction without ST-segment elevation in the Republic of Moldova

    by Mihail Popovici, Victoria Ivanov, Olga Dicusar, Ion Moraru, Lucia Ciobanu, Ion Popovici, Tatiana Dănilă, Carolina Dumanschi, Stela Fuior, Victoria Tofan, et al.

    Purpose: To evaluate the quality of NSTEMI care in AMI centers and to identify potential gaps in the management of patients with this diagnosis.Material and methods: 550 patients with NSTEMI, hospitalized in 3 coronary angioplasty centers were enrolled in the study. The information was collected using a questionnaire composed of 179 questions, developed according to the standards of the EORP NSTEMI Registry. The research took place in two stages: retrospective observational study during 2019 and prospective in the period 01.2020-09.2022.Results. The NSTEMI rate from the total number of patients hospitalized with AMI in the Institute of Cardiology and SP Novamed, in the period 2019-2022 was 21,6%. The results of the evaluation of NSTEMI management in the studied AMI centers are close to those reported by equivalent international registries (EORP NSTEMI, FAST-MI, PLACS, MINAP), excepting some differences in certain chapters: the diagnostic strategy of NSTE-ACS, risk stratification, diagnosis and treatment of hypercholesterolemia and the antiplatelet treatment indicated at discharge. The mortality rate in the hospital was 4,2%, at 30 days m8k6,0%, at 6 months after hospitalization 10,2%, and at 12 months 12,8%. Conclusions. The rate of NSTEMI in the Republic of Moldova is lower than that reported by the international registers of IMA, while the mortality indicators are higher. These discrepancies are largely explained by gaps in NSTEMI management identified within the studied AMI centers.

  • Open Access

    NETosis and non-ST elevation acute myocardial infarction: pathophysiological significance and circulating markers

    by Mihail Popovici, Victoria Ivanov, Ion Popovici, Lucia Ciobanu, Mihaela Munteanu, Ion Moraru, Valeriu Cobet

    Scop. Evaluarea rolului morții neutrofilelor (NET-ozei) în evoluția infarctului miocardic acut fără elevarea segmentului ST (NSTEMI) prin aprecierea nivelurilor circulante de admitere în staționar ale markerilor care au în plan fiziopatologic tangență la acest fenomen. Material și metode. Cercetarea s-a realizat pe un lot de 54 de pacienți cu NSTEMI, supuși angioplastiei coronariene în laboratorul de cardiologie intervențională în cadrul proiectului științific din cadrul Programului de stat, la care prin metoda ELISA s-a determinat conținutul seric al 7 markeri biochimici: Selectina E, moleculei de adeziune intercelulare 1(ICAM-1), fosfolipaza 2(PhA2), interleukina 8 (IL-8), elastaza neutrofilelor ( EN), mieloperoxidaza (MPO) și metaloproteinaza 8 (MMP-8). Lotul de control a fost format din 30 de persoane aparent sănătoase. Rezultate. Rezultatele obținute indică prezența devierilor incrementale semnificative ale tuturor markerilor explorați la pacienții cu NSTEMI în comparație cu nivelul control. Markerii mai specifici ai NETozei (MPO, EN și MMP-8) au excelat prin rata maximă de elevare în ser, decelată în limitele 88-151%. Ceilalți markeri au avut o rată de creștere a nivelurilor lor circulante de 50-74%. Concluzie. La pacienții cu NSTEMI nivelurile circulante de admitere ale markerilor specifici ai NET-ozei, mieloperoxidaza, elastaza neutrofilelor și MMP-8 sunt elevate cu 88-151% față de control, fapt ce indică asupra rolului patogenetic al NET-ozei și, totodată, invocă plauzibil acestor markeri valoare predictivă diagnostică și prognostică.


  • Open Access

    The role of intestinal dysbiosis in endothelial dysfunction evolution in patients with microvascular angina

    by Mihail Popovici, Lorenzo Loffredo, Victoria Ivanov, Ion Popovici, Lucia Ciobanu, Mihaela Munteanu, Valeriu Cobet

    Purpose. Evaluation of circulating levels of lipopolysaccharide and zonulin in conjunction with markers of endothelial dysfunction, inflammation, and oxidative stress in patients with microvascular angina (MА). Material and methods. The study was carried out in a group of 58 patients with MA hospitalized in the Institute of Cardiology. The determination of circulating levels of 20 biomarkers was carried out in cooperation with the laboratory investigation center of Sapienza University (Italy). All functional and biochemical markers were also determined in 48 apparently healthy people (control group) with the values of which the markers of MA patients were compared. Results. Endothelial dysfunction in patients with MA excelled by increasing the thickness of the intima-media complex of the carotid artery by 41%, as well as by reducing of flow-mediated brachial artery dilatation (FMD) by 31,6%. The presence of dysbiosis was manifested by an 80% increase in the serum content of lipopolysaccharides (LPS) and by doubling of zonulin (1,8±0,3 vs 3,6±0,7 ng/ml). Endothelial dysfunction and dysbiosis evolved in association with oxidative stress activation estimated by means of 6 markers and increased serum content of 6 important pro-inflammatory markers (hsCRP, IL-6, TNF-α, etc.) Conclusions. 1. In patients with MA, elevated circulating levels of LPS and zonulin more than twice compared to the control value were found, which indicates the presence of intestinal dysbiosis. 2. LPS and zonulin correlate robustly with morphofunctional and biochemical markers of endothelial dysfunction, as well as with markers of its main pathogenetic factors, - inflammation and oxidative stress.

  • Open Access

    Multi-marker panel in patients with NSTEMI: pillars of pathogenesis and diagnostics

    by Mihail Popovici, Victoria Ivanov, Ion Popovici, Lucia Ciobanu, Mihaela Munteanu, Valeriu Cobets

    Aim. Assessment within the multi-marker panel applied to patients with NSTEMI of admission levels of the main markers of cardiovascular pathology in order to disentangle the pathogenetic interface and identify diagnostic predictors. Material and methods. The research was carried out on a group of 87 patients with NSTEMI, exposed to angioplas-ty, in which the admission values of 2 morphofunctional markers of endothelial dysfunction were determined, as well as the serum levels of 53 biochemical markers with reference to: inflammation, oxidative stress, endothelial dysfunction, cell injury, hemostasis disorder, myocardial and extracellular matrix (ECM) remodeling. The control group has consisted of 40 apparently healthy people.Results. The analysis of the multi-makrer panel revealed significant deviations of the majority of the explored markers compared to the control level. Endothelial dysfunction was marked by the increase of thickness of the medial-intima complex of the carotid artery and the decrease of the flow-mediated dilation of brachial artery in association with a 7694% raise of endothelial cell fragments (EF), phospholipase A2 (PhA2) and angiopoietin 2 (Ang 2). Among 16 markers of inflammation, the elevation of myeloperoxidase (MPO) by 156% is remarkable as a specific marker of NETosis. Activated oxidative stress is the result of the impairment of the antioxidant defense, and hemostasis disorder must be underlined by double increase of fibrin monomers (FM). From a pathogenetic point of view, the multiple increase (more than 8 times) of cardiac myosin-binding protein (cMyBP-C) is important and understandable, and the markers of myocardial and ECM remodeling basically demonstrated an activation of several types of metalloproteinases. Conclusion. From the spectrum of the multi-marker panel applied to patients with NSTEMI, markers with plausible diagnostic value due to inteligibly reflected pathogenetic mechanism are highlighted as: MPO, PhA2, Ang 2, EF, FM, and cMyBP-C.


  • Features of hemostasis in patients with non-ST-elevation myocardial infarction

    by Mihail Popovici, Lucia Ciobanu, Victoria Ivanov, Mihaela Ivanov, Ion Ion Popovici, Tatiana Danila, Valeriu Cobet

    Background: Coronary thrombosis is the key pathogenic mechanism of acute heart attack, including non-ST segment elevation (NSTEMI). Given that, the detection of reliable markers of hemostasis disorders is important in the process of optimizing the diagnosis of NSTEMI. Material and methods: The study was conducted on 54 patients with NSTEMI (average age 69.7±1.5 years). In 60% of cases, 3-vessel disease was noted; 56% of patients had ejection fraction >50%, and Killip class I of heart failure was revealed in 78% of patients. With the help of the STA-Liatest (France) equipment, the blood tests determined the following hemostasis markers: fibrin monomers (FM), thrombotic complex activity of factors II, VII and X. Additional markers like Procoag, the coagulation indicator dependent on circulating phospholipids or SPA, D-dimers, as well as factors C, S and antithrombin III were appreciated. The values of these markers determined by the same method in 20 healthy persons (control group) were used as normal values. Results: Circulating level of FM on admission was increased twice, while the values of Procoag and SPA were significantly decreased by 35.3% compared to the control. Factors C, S and antithrombin III were 54-80% of the control value range, and D-dimers were within the permissible values. In the acute phase of the heart attack, a deterioration of hemostasis indicators was noted, excepting the D-dimers. The levels of FM determined 24 and 72 hours after revascularization were consistently increased (up to 3.8 times) compared to the control, while Procoag and SPA decreased by 54-57%. Further reduction of factors C, S and antithrombin III accounted for 42-54% of normal indicators. After 5 days, an improvement in hemostasis markers was observed, but a significant difference still remained comparing to the control group. Conclusions: The hemostasis particularities discovered in patients with NSTEMI indicate the features of an activated prothrombotic status, and FM could be an important diagnostic marker of NSTEMI, due to its most significant deviation from the normal value (>100%). It can reliably reflect the thrombin level, which triggers the last enzymatic phase of thrombus formation.

  • Cardiovascular risk profile in patients with hepatic steatosis

    by Angela Peltec, Victoria Ivanov, Ines Toaca, Sergiu Matcovschii

    Background. Fatty liver disease (FLD) is composed of a wide spectrum including metabolic associated fatty liver disease (MAFLD). Cardiovascular disease (CVD) is the leading cause of mortality in this populational group. Many risk estimation systems are in existence for improving the management of population groups, but currently, none of the available risk prediction models are authenticated in patients with hepatic steatosis. Materials and methods. Transversal, observational, prospective, case control study has been included 680 patients with MAFLD and 96 control subjects without MAFLD. Experimental group was divided in tree subgroups: A - overweight or obesity (BMI ≥ 25 kg/m2 ) N= 498; B – lean/normal weight (BMI <25kg/m2 ) N= 58 and C – Type 2 diabetes mellitus N= 156. For each patient, cardiovascular risk was estimated using the Framingham equation (risk ≥ 20% – high), SCORE risk chat (risk ≥ 10% – high) and Atherosclerotic Cardiovascular Disease Risk Algorithm from the American College of Cardiology and the American Heart Association (AHA/ACC) (risk ≥ 20% – high). Results. Model Risk SCORE and Risk ACC/AHA had identified the low proportion of patients with high risk, however, Risk FRS determined the highest proportion of the patients as being ‘at high-risk’ (Risk SCORE -7% vs Risk ACC/AHA - 15% vs Risk FRS - 38%, p <0.001). Statistically significant correlations were found between the scoring systems Risk FRS and Risk ACC/AHA (Pearson’s r = 0.939, p = 0.0001, Spearman`s rho=0.960, p <0.001). The highest proportion of the patients as being ‘at high-risk’ from group C – DMT2 was found by model RiskFRS – 82.7%, with statistically significant difference between group A and B – 28.1 % vs 6.8%, p < 0.001. The same tendency was observed for RiskSCORE and Risk ACC/AHA (RiskSCORE DMT2 – 26.3% vs Risk ACC/AHA DMT2 – 46.8%), bur these scores have identified the low proportion of patients with high risk in this populational group. Conclusions. The study shows that RiskFRS appeared to be most useful CVD risk assessment model in hepatic steatosis, RiskFRS is likely to identify a greater number of patients at ‘high-risk’ as compared to Risk SCORE and Risk ACC/AHA.